💜 It’s Dravet Syndrome Awareness Day and DSF staff is proud to show up for our community. Share your photo, raise your voice, and help turn awareness into action.

🟣 Check out our Awareness Month resources: bit.ly/3q4arIH

#CureDravet

Your support and involvement with DSF are helping to shape a brighter future for individuals and families affected by Dravet syndrome. We invite you to explore our 2024 Annual Report, which highlights the incredible progress we've made together over the past year.

Learn more: bit.ly/3YR1roM

For families navigating Dravet syndrome, finding new treatment options offers hope. The Phase 3 ARGUS Trial is currently enrolling patients with Dravet syndrome to test if Clemizole (EPX-100) can reduce seizure frequency.

Read our blog to learn more: bit.ly/4d0h1Eq

#CureDravet

Phase 3 trials for zorevunersen (STK-001) — a treatment targeting the genetic cause of Dravet syndrome — are expected to begin this summer.

We’ve created an in-depth FAQ to help you understand where things stand and what’s next.

🦋 Read the full FAQ blog: bit.ly/41EZtZe

#CureDravet #DravetSyndrome

New DSF-funded study finds impaired cellular energy metabolism in kids with #DravetSyndrome — adding key insights to how we understand this disease. 🧬 Thank you to our donors who make research like this possible! 💜 #EpilepsyResearch #DSFImpact

📖 Read: bit.ly/42h9ZWH

Explore "Expert Perspectives on Dravet Syndrome Management" with Dr. Scott Perry (@thenotoriouseeg.bsky.social), covering diagnosis, emerging therapies, and care strategies. Gain valuable insights here: bit.ly/4fHiMab #DSF #DravetSyndrome